Jeune

What Jeune does

Jeune Inc. is a clinical-stage biotechnology company, headquartered in Pittsburgh, Pennsylvania, that develops a portfolio of gene-based treatments for aesthetic skin conditions. Founded in April 2019 as a wholly-owned subsidiary of Krystal Biotech, the company leverages a clinically validated, skin-optimized HSV-1-based gene delivery platform to introduce effector genes into key skin cells, stimulating the patient's own cells to produce structural proteins such as Type I, III, and IV collagen and elastin that decline with intrinsic aging and extrinsic photo-damage. The pipeline comprises five candidates — KB301 (Type III collagen), KB302 (Type I collagen), KB303 (elastin), KB304 (Type III collagen + elastin combination), and KB305 (Type IV collagen) — spanning Discovery through Phase 1 development.

The lead programs, KB301 and KB304, have generated positive Phase 1 readouts: PEARL-1 showed efficacy and durability for KB301 in fine lines and wrinkles (2022), with additional interim safety/efficacy results in lateral canthal lines and dynamic décolleté wrinkles reported in August 2024, and the PEARL-2 study of KB304 reported significant aesthetic improvements for moderate-to-severe décolleté wrinkles in July 2025. The company has filed no independently disclosed funding rounds, executes no commercial sales, and has no marketed products; all clinical communications and pipeline updates are disseminated via Krystal Biotech's investor relations channel and through dermatology/aesthetics conference presentations (including ASDS and SID).

Jeune does not yet have a revenue model in operation — no products are approved, no pricing has been set, and distribution channels are not established. The subsidiary is led by CEO Marc Forth (appointed April 2025) and CFO Nishant Saxena (appointed January 2025), with strategic oversight from Krystal Biotech executives Krish Krishnan (Chairman/CEO, Board Member) and Suma Krishnan (Founder of Krystal Biotech). Capital is sourced through its parent, and the target end customer — once commercial launch occurs — is the adult population seeking to address visible signs of skin aging (wrinkles, fine lines, loss of elasticity) via minimally invasive, mechanism-driven gene therapies rather than traditional topical or injectable aesthetic modalities.

Name

Jeune

Legal name

Jeune, Inc.

Website

https://jeuneinc.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Jeune is a Pittsburgh-based, clinical-stage biotechnology subsidiary of Krystal Biotech developing gene-based aesthetic treatments using an HSV-1 delivery platform to stimulate endogenous collagen and elastin production, targeting adults with aging or photo-damaged skin via a five-program pipeline (KB301–KB305) currently in Phase 1.

Ownership category

akta.pro rank

Headquarters

HQ city

Pittsburgh

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Marketing channels2 records

Core offering

Jeune develops gene-based aesthetic treatments using a skin-optimized HSV-1 gene delivery platform originally validated by Krystal Biotech. Its pipeline of five candidates (KB301, KB302, KB303, KB304, KB305) targets delivery of collagen and elastin genes into skin cells to stimulate patients' own production of structural proteins that decline with aging and photo-damage. No products have been commercially launched; all programs are in clinical or preclinical development.

Product overview

Jeune is a biotechnology company developing a portfolio of gene-based aesthetic treatments leveraging a clinically validated HSV-1 gene-delivery platform. The platform enables targeted delivery of effector genes into skin cells to stimulate patient cells to produce structural proteins that decline with aging and photo-damage. The pipeline consists of five product candidates: KB301 (Type III collagen), KB302 (Type I collagen), KB303 (Elastin), KB304 (Type III collagen + elastin combination), and KB305 (Type IV collagen). These candidates address various aesthetic conditions including wrinkles, fine lines, and skin elasticity, with programs progressing through Phase 1 clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• KB301 Investigational gene therapy candidate delivering the COL3A1 gene (Type III collagen) for treatment of aesthetic conditions including lateral canthal lines (crow's feet), décolleté wrinkles, and fine lines. Utilizes the skin-optimized HSV-1-based gene delivery platform to stimulate patients' own production of Type III collagen in targeted skin cells. Evaluated in Phase 1 PEARL-1 clinical study.
• KB302 Investigational gene therapy candidate targeting Type I collagen expression for aging skin through the skin-optimized HSV-1 gene delivery platform. Intended to stimulate patients' own production of Type I collagen, a primary structural protein of skin.
• KB303 Investigational gene therapy candidate delivering elastin for improvement of skin elasticity. HSV-1-based gene therapy designed to address loss of skin elasticity associated with aging and photo-damage. Preclinical data was presented at ASDS 2021.
• KB304

Quantifiable outcome

• Phase 1 PEARL-1 study demonstrated positive safety and efficacy results for KB301 in improvement of fine lines and wrinkles (March 2022); durability results confirmed sustained improvements in the extension cohort (November 2022)
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators2 records

Recent moves6 records

Expansion highlights3 records

Broad incumbents

• Evolus: Commercial-stage aesthetics company (Jeuveau/prabotulinumtoxinA) competing in neuromodulators. Comparable business model: focused aesthetics company monetizing injectables in cash-pay channels.
• AbbVie (Allergan Aesthetics): Owns Allergan Aesthetics, the Botox franchise and the largest neuromodulator/filler portfolio globally. Represents the entrenched competitor whose market share Jeune's gene therapy would need to erode.
• Galderma: Global pure-play dermatology/aesthetics company with leading positions in injectables, fillers, and skincare. Comparable as the dominant incumbent in the addressable aesthetic market Jeune is targeting with gene therapy.
• Hugel: Korean-listed aesthetics company with botulinum toxin (Botulax) and HA filler products sold globally. Comparable as a multinational aesthetics injectable competitor with established commercial channels.
• Revance Therapeutics: Aesthetics-focused biotechnology company behind the DaxibotulinumtoxinA neuromodulator (DAXXIFY) and a portfolio of injectable aesthetic products. Directly comparable cash-pay aesthetics biotech profile, now part of Crown Laboratories.
• Croma-Pharma: Austrian aesthetics company with hyaluronic acid filler portfolio and growing global presence. Comparable as an aesthetics-focused, multi-product incumbent competing for physician and consumer mindshare in the same addressable market.

Emerging players

• Stemson Therapeutics: Private pre-clinical biotech using iPSC-derived cells and regenerative biology to treat hair loss. Comparable as an emerging regenerative-medicine player pursuing aesthetic/cosmetic indications through novel cell- and gene-based mechanisms.

Direct peers

• Castle Creek Biosciences: Late-clinical gene therapy company developing treatments for rare dermatological conditions (e.g., recessive dystrophic epidermolysis bullosa). Shares Jeune's combination of gene therapy and skin-focused indications and similar clinical-stage development profile.
• Krystal Biotech: Parent company and developer of the HSV-1 gene-delivery platform Jeune is built on. Most directly comparable in vector technology and gene-therapy CMC capabilities; operates in rare-disease dermatology (Vyjuve for DEB) rather than aesthetics, so no commercial overlap but highly aligned technical approach.
• Abeona Therapeutics: Clinical-stage gene therapy company with dermatology-adjacent programs (EB-101 for recessive dystrophic epidermolysis bullosa). Comparable as a small-cap gene-therapy biotech targeting skin indications, although using different (cultured epidermal autograft) technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jeune